Archiwum zdjęć stockowych 2024

EN_01631302_0226

30,00 EUR Private use
Making print for private purpose, storage in computer memory, no distribution rights.
40,00 EUR Internet - private use
Strictly for editorial, single use on a personal (nonprofit) web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.
75,00 EUR Internet commercial use
Strictly for editorial, single use on a commercial web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.
90,00 EUR Print use
Strictly for editorial, single use, inside of newspaper, magazine, book (including digital version), one edition, one single country. Not for resale.

Gross prices

caption

Semaglutide (GLP-1) weight-loss drug Wegovy, made by pharmaceutical company Novo Nordisk, which are designed to treat type 2 diabetes, but are widely known for their effect on weight loss. Picture date: Wednesday October 16, 2024.

headline Archiwum zdjęć stockowych 2024

created date 2024-10-16

credit James Manning/Press Association/East News

source Press Association

byline James Manning

original transmission reference 77823482

weight 1,06MB

size 40cm x 26cm by 300dpi

keywords - Show

1, 16, 2, 2024, AGONIST, ARE, BUT, BY, COMPANY, DATE, DESIGNED, DIABETES, DIET, DIETS, DRUG, DRUGS, EFFECT, FOR, GLP-1, GLUCAGON-LIKE, HEALTH, inhectable, INJECTION, JAB, JAMES, KNOWN, LONDON, LOSS, MADE, MANNING, MEDICATION, MEDICINE, NORDISK, NOVO, OBESITY, OCTOBER, ON, pa2024, PEPTIDE, PHARMACEUTICAL, PICTURE, RECEPTOR, SEMAGLUTIDE, THEIR, TO, TREAT, TYPE, UK, WEDNESDAY, wegovy, WEIGHT, WEIGHT-LOSS, WHICH, WIDELY,